Zika virus was first discovered in Ughanda in 1947 in monkeys infected by the virus through bites from of infected Aedes species mosquitos. Zika virus has become a highly researched disease due to increase in incidences from 2007 to 2016, when the virus spread eastward, across the Pacific Ocean to the Americas. In 2015–16 Zika virus epidemic reached pandemic levels. The Zika envelope protein composes the majority of the virion surface and it is involved with replication, such as host cell binding and membrane fusion.
The symptoms of Zika infection vary from non-existant to visible rash, fever, headaches and conjunctivitis. It is usually non life threatening, but has been associated to microcephaly in unborn fetuses when passed by an infected pregnant mother.
Recombinant protein corresponding to Zika Virus Envelope, expressed in E. coli.
Assay Information:This protein binds to Zika converted human serum polyclonal antibodies and cross reacts with Dengue virus converted human serum polyclonal antibodies.
Applications:Suitable for use in ELISA, Western Blot and Lateral Flow. Other applications not tested.
Recommended Dilutions:ELISA: 1-2 ug/ml protein range for titering Dengue virus converted human polyclonal antibodiesLateral Flow: 1-2mg/ml (1-2ul/cm)Optimal dilutions to be determined by the researcher.
Storage and Stability:Aliquot to avoid repeated freezing and thawing and store at -70°C. Aliquots are stable for 6 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
仕様
Size：100ug
Source Antigen：Recombinant, E. coli
Grade：Highly Purified
Purity：≥95% (SDS-PAGE)
Form：Supplied as liquid in 50mM NaPO4, pH 8.5, 50mM sodium chloride, 0.02% SDS.
